Treatment of acute kidney allograft rejection with the nonmitogenic CD3 mAb CLB T3/4.A (IgA-CD3): absence of a correlation of clinical responsiveness with inhibition of lymphocyte reactivity in vitro

Transplant Proc. 2001 Feb-Mar;33(1-2):1229-30. doi: 10.1016/s0041-1345(00)02399-x.

Authors

R T Meijer¹, S L Yong, S Surachno, I J ten Berge, P T Schellekens

Affiliation

¹ Renal Transplant Unit, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

PMID: 11267271
DOI: 10.1016/s0041-1345(00)02399-x

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Antibodies, Monoclonal / therapeutic use*
CD3 Complex / immunology*
Graft Rejection / immunology
Graft Rejection / therapy*
Humans
Immunoglobulin A / immunology*
Kidney Transplantation / immunology*
Lymphocyte Activation / immunology*
Lymphocytes / immunology*
Muromonab-CD3 / therapeutic use
Time Factors
Transplantation, Homologous

Substances

Antibodies, Monoclonal
CD3 Complex
Immunoglobulin A
Muromonab-CD3